Haleon PLC maintains a decent presence in the market with mixed messages from various financial entities. Berenberg bank, Jefferies and Barclays are maintaining a buy rating on HLN amid challenging market dynamics. Their stock performance has been slightly volatile, recently falling by 3.4% due to a shortfall on the company's own medium-term target. The pharmaceutical giant's Q4 sales have stirred concern after falling short of expectations, contributing to a fall in share price. Major shareholder movements have been highlighted with Cantor Fitzgerald L.P acquiring a significant amount of shares and Orion Portfolio Solutions LLC selling off a portion of their own. Haleon announced a £500m buyback to cancel shares by Aug 2026 and the establishment of a £65m toothpaste plant to address widespread oral health issues in China. It remains unclear if these moves are a part of a turnaround strategy given the stark financial assessment by Jim Cramer stating Haleon's \"stock’s been struggling\". Despite this, Haleon’s financial prospects still look promising and investment experts foresee a turning point in its Consumer-Health story by 2026.
Haleon Stocks News Analytics from Thu, 01 May 2025 07:00:00 GMT to Fri, 20 Mar 2026 05:58:14 GMT -
Rating 0
- Innovation 2
- Information 8
- Rumor 3
